Clinical and post-licensure data have demonstrated that AS03-adjuvanted inactivated split
virion vaccines, many with reduced antigen content, are effective against influenza infection …

Background: Universal and timely administration of a prepandemic vaccine is considered to
be one of the most effective measures to reduce the incidence of pandemic influenza …

Background Almost 700 cases of human infection with avian influenza A/H7N9 have been
reported since 2013. Pandemic preparedness strategies include H7N9 vaccine …

Background. The current US national stockpile of influenza H5 vaccine was produced using
the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease …

The immunogenicity and lot-to-lot consistency of an AS03-adjuvanted H5N1 vaccine were
evaluated in 1206 Asian adults, randomised to receive two doses of adjuvanted (3.75 μg …

On February 17–18, 2011, the World Health Organization convened the 7th meeting on “The
Evaluation of Pandemic Influenza Vaccines in Clinical Trials” to review the progress made …

Background. The tocopherol-based oil-in-water emulsion adjuvant system family (AS03)
improves antigen sparing with split-virion H5N1 influenza vaccines, representing an …

Importance Human infections with the avian influenza A (H7N9) virus were first reported in
China in 2013 and continue to occur. Hemagglutinin H7 administered alone is a poor …

Please cite this paper as: Yin et al.(2011) Immunogenicity and safety of pandemic influenza
A (H1N1) 2009 vaccine: systematic review and meta‐analysis. Influenza and Other …

Abstract (See the editorial commentary by Neuzil, on pages 700–1.) Background. In this
study (NCT00985088) we evaluated different formulations of an H1N1 2009 pandemic …